Claims
- 1. A method of treating male erectile disorder in a male human, who is in need of such treatment, which comprises oral administration in a single daily dose of from about 0.5 thru about 5 mg of a compound selected from the group consisting of:(5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one and (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and pharmaceutically acceptable salts thereof to the human.
- 2. A method of treating male erectile disorder according to claim 1 where the compound (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one.
- 3. A method of treating male erectile disorder according to claim 2 where the compound is (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1).
- 4. A method of treating male erectile disorder according to claim 1 where the compound of formula (A) is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione.
- 5. A method of treating male erectile disorder according to claim 1 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH3—(CH2)n—COOH where n is 0 thru 4, HOOC—(CH2)n—COOH where n is as defined above.
- 6. A method of treating male erectile disorder according to claim 1 where the amount of the compound is from about 1 thru about 3 mg/person/dose.
- 7. A method of treating male erectile disorder according to claim 1 where the compound is administered from about 10 minutes to about 8 hr prior to sexual activity.
- 8. A method of treating male erectile disorder according to claim 7 where the compound is administered from about 0.5 hr to about 1 hr prior to sexual activity.
- 9. A method of treating male erectile according to claim 8 where the compound is administered about 0.5 hr prior to sexual activity.
- 10. A method of treating male erectile according to claim 1 where the human does not have Parkinson's disease.
- 11. A method of treating male erectile according to claim 1 where the human does not experience postural hypotension.
- 12. A method of treating male erectile according to claim 1 where the compound is used in combination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where both the compound is administered within 8 hours prior to sexual activity and the vascular smooth muscle relaxation agent is administered to the human within a sexually effective time period prior to sexual activity.
- 13. A method of treating male erectile according to claim 12 where the vascular smooth muscle relaxation agents is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin E1 receptor agonists (PGE1) and vasoactive intestinal polypeptide (VIP) agents.
- 14. A method of treating male erectile according to claim 13 where the vascular smooth muscle relaxation agents is selected from the group consisting of sildenafil, ICOS-351, milrinone, papaverine, linsidomine, phentolamine, yohimbine, prostaglandin E1 (PGE1) and VIP.
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the following provisional applications: U.S. Ser. No. 60/120,543, filed Feb. 17, 1999; U.S. Ser. No. 60/115,922, filed Jan. 14, 1999; U.S. Ser. No. 60/115,051, filed Jan. 8, 1999; and U.S. Ser. No. 60/114,840, filed Jan. 6, 1999, under 35 USC §119(e)(1).
US Referenced Citations (7)
Number |
Name |
Date |
Kind |
4127118 |
Latorre |
Nov 1978 |
A |
4801587 |
Voss et al. |
Jan 1989 |
A |
5250534 |
Bell et al. |
Oct 1993 |
A |
5273975 |
Moon et al. |
Dec 1993 |
A |
5541211 |
Pertovaara et al. |
Jul 1996 |
A |
5770606 |
El-Rashidy et al. |
Jun 1998 |
A |
5773020 |
Place et al. |
Jun 1998 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO94282902 |
Dec 1994 |
WO |
Non-Patent Literature Citations (4)
Entry |
International Journal of Impotence Research, 10 (Supplement 3), Aug. 1998, Abstracts #417 and 419. |
Brain Research, 55,383-389 (1973). |
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV), American Psychiatric Association, Washington DC (1994). |
DSM-IV Guidebook, American Psychiatric Press, Inc., Washington DC 1995. |
Provisional Applications (4)
|
Number |
Date |
Country |
|
60/120543 |
Feb 1999 |
US |
|
60/115922 |
Jan 1999 |
US |
|
60/115051 |
Jan 1999 |
US |
|
60/114840 |
Jan 1999 |
US |